GlaxoSmithKline Historical Income Statement

GSK Stock  USD 42.92  0.07  0.16%   
Historical analysis of GlaxoSmithKline PLC income statement accounts such as Total Revenue of 19.9 B or Gross Profit of 14.6 B can show how well GlaxoSmithKline PLC ADR performed in making a profits. Evaluating GlaxoSmithKline PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of GlaxoSmithKline PLC's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Income Statement Analysis

GlaxoSmithKline PLC ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to GlaxoSmithKline PLC shareholders. The income statement also shows GlaxoSmithKline investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

GlaxoSmithKline PLC Income Statement Chart

GlaxoSmithKline PLC ADR Income Statement is one of the three primary financial statements used for reporting GlaxoSmithKline's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of GlaxoSmithKline PLC ADR revenue and expense. GlaxoSmithKline PLC Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, GlaxoSmithKline PLC's Extraordinary Items is quite stable compared to the past year. Reconciled Depreciation is expected to rise to about 1.7 B this year, although the value of Total Revenue will most likely fall to about 19.9 B.

Total Revenue

Total revenue comprises all receipts GlaxoSmithKline PLC ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of GlaxoSmithKline PLC ADR minus its cost of goods sold. It is profit before GlaxoSmithKline PLC operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of GlaxoSmithKline PLC ADR. It is also known as GlaxoSmithKline PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from GlaxoSmithKline PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of GlaxoSmithKline PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most accounts from GlaxoSmithKline PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's Extraordinary Items is quite stable compared to the past year. Reconciled Depreciation is expected to rise to about 1.7 B this year, although the value of Total Revenue will most likely fall to about 19.9 B.
 2021 2022 2023 2024 (projected)
Interest Expense784M879M775M502.2M
Depreciation And Amortization2.6B2.4B2.3B1.2B

GlaxoSmithKline PLC income statement Correlations

0.60.660.630.70.210.210.650.490.710.15-0.120.110.040.550.660.07-0.58-0.02-0.460.21-0.20.23
0.60.940.940.910.680.670.90.790.890.59-0.030.570.270.80.880.11-0.90.02-0.28-0.06-0.350.33
0.660.940.990.980.560.560.940.70.960.46-0.190.430.130.90.960.0-0.86-0.11-0.54-0.08-0.450.38
0.630.940.990.950.560.560.940.690.940.46-0.230.420.160.880.92-0.08-0.88-0.17-0.52-0.12-0.430.32
0.70.910.980.950.480.480.890.640.990.39-0.170.350.090.890.970.09-0.85-0.04-0.560.02-0.380.37
0.210.680.560.560.481.00.590.950.420.990.590.970.60.540.520.51-0.610.540.08-0.16-0.250.16
0.210.670.560.560.481.00.590.950.420.990.590.970.610.540.520.51-0.610.550.09-0.16-0.240.15
0.650.90.940.940.890.590.590.720.870.49-0.140.490.080.780.88-0.04-0.82-0.09-0.54-0.28-0.490.37
0.490.790.70.690.640.950.950.720.590.930.490.890.560.650.670.48-0.720.48-0.06-0.08-0.280.2
0.710.890.960.940.990.420.420.870.590.33-0.220.280.120.860.930.05-0.87-0.06-0.560.02-0.290.28
0.150.590.460.460.390.990.990.490.930.330.670.970.650.470.430.58-0.540.620.17-0.13-0.180.12
-0.12-0.03-0.19-0.23-0.170.590.59-0.140.49-0.220.670.70.42-0.09-0.120.840.050.930.470.080.13-0.03
0.110.570.430.420.350.970.970.490.890.280.970.70.480.420.410.56-0.490.620.18-0.21-0.260.17
0.040.270.130.160.090.60.610.080.560.120.650.420.480.140.050.46-0.340.490.330.160.33-0.26
0.550.80.90.880.890.540.540.780.650.860.47-0.090.420.140.950.12-0.820.01-0.6-0.13-0.570.35
0.660.880.960.920.970.520.520.880.670.930.43-0.120.410.050.950.12-0.82-0.01-0.63-0.09-0.550.45
0.070.110.0-0.080.090.510.51-0.040.480.050.580.840.560.460.120.12-0.10.960.240.150.120.02
-0.58-0.9-0.86-0.88-0.85-0.61-0.61-0.82-0.72-0.87-0.540.05-0.49-0.34-0.82-0.82-0.1-0.060.320.130.22-0.08
-0.020.02-0.11-0.17-0.040.540.55-0.090.48-0.060.620.930.620.490.01-0.010.96-0.060.320.080.18-0.09
-0.46-0.28-0.54-0.52-0.560.080.09-0.54-0.06-0.560.170.470.180.33-0.6-0.630.240.320.320.390.64-0.29
0.21-0.06-0.08-0.120.02-0.16-0.16-0.28-0.080.02-0.130.08-0.210.16-0.13-0.090.150.130.080.390.550.17
-0.2-0.35-0.45-0.43-0.38-0.25-0.24-0.49-0.28-0.29-0.180.13-0.260.33-0.57-0.550.120.220.180.640.55-0.54
0.230.330.380.320.370.160.150.370.20.280.12-0.030.17-0.260.350.450.02-0.08-0.09-0.290.17-0.54
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization3.2B701M2.6B2.4B2.3B1.2B
Interest Expense912M892M784M879M775M502.2M
Total Revenue33.8B34.1B34.1B29.3B30.3B19.9B
Gross Profit21.9B22.4B22.5B19.8B21.3B14.6B
Other Operating Expenses26.8B26.3B27.9B22.9B23.3B15.3B
Operating Income7.0B7.8B6.2B6.4B7.0B5.0B
Ebit7.0B7.8B6.2B6.4B7.0B5.2B
Research Development4.6B5.1B5.3B5.5B5.2B3.0B
Ebitda10.1B8.5B8.8B8.8B9.3B6.4B
Total Operating Expenses14.9B14.6B16.3B13.3B14.3B10.0B
Income Before Tax6.2B7.0B5.4B5.6B6.1B4.8B
Total Other Income Expense Net(740M)(815M)(759M)(805M)(924M)(877.8M)
Net Income4.6B5.7B4.4B4.9B4.9B3.4B
Income Tax Expense953M580M346M707M756M1.2B
Selling General Administrative11.4B11.5B11.0B8.4B9.4B9.8B
Cost Of Revenue11.9B11.7B11.6B9.6B9.1B7.7B
Net Income Applicable To Common Shares4.6B5.7B4.4B15.0B13.5B14.1B
Minority Interest7.0B6.2B(711M)(665M)(380M)(361M)
Net Income From Continuing Ops5.3B6.4B5.1B4.9B6.5B9.4B
Tax Provision953M580M346M707M756M669.3M
Interest Income708M44M723M76M48M45.6M
Net Interest Income(840M)(848M)(756M)(803M)(735M)(771.8M)
Reconciled Depreciation2.3B2.4B2.5B2.3B1.5B1.7B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.02
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.